Home Tags Anti-CD79b

Tag: anti-CD79b

Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...

Peter Hofland
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

Updates from the 14th International Conference on Malignant Lymphoma (ICML)

Peter Hofland
Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...

Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...

Peter Hofland
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...

Brianza Nyborg
Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X